G-quadruplexes: a Promising Target for Cancer Therapy

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2021 Feb 26

PMID 33632214

Citations 144

Authors

Nils Kosiol

Stefan Juranek

Peter Brossart

Annkristin Heine

Katrin Paeschke

Affiliations

Soon will be listed here.

Abstract

DNA and RNA can fold into a variety of alternative conformations. In recent years, a particular nucleic acid structure was discussed to play a role in malignant transformation and cancer development. This structure is called a G-quadruplex (G4). G4 structure formation can drive genome instability by creating mutations, deletions and stimulating recombination events. The importance of G4 structures in the characterization of malignant cells was currently demonstrated in breast cancer samples. In this analysis a correlation between G4 structure formation and an increased intratumor heterogeneity was identified. This suggests that G4 structures might allow breast cancer stratification and supports the identification of new personalized treatment options. Because of the stability of G4 structures and their presence within most human oncogenic promoters and at telomeres, G4 structures are currently tested as a therapeutic target to downregulate transcription or to block telomere elongation in cancer cells. To date, different chemical molecules (G4 ligands) have been developed that aim to target G4 structures. In this review we discuss and compare G4 function and relevance for therapeutic approaches and their impact on cancer development for three cancer entities, which differ significantly in their amount and type of mutations: pancreatic cancer, leukemia and malignant melanoma. G4 structures might present a promising new strategy to individually target tumor cells and could support personalized treatment approaches in the future.

Citing Articles

A novel L-RNA aptamer to regulate the pUG fold RNA-induced gene expression in vivo.

Liew S, Cao D, Petersen R, Butcher S, Kennedy S, Kwok C Nucleic Acids Res. 2025; 53(5).

PMID: 40057375 PMC: 11890061. DOI: 10.1093/nar/gkaf137.

G-Quadruplex Structures Formed by Human Telomere and GGGGCC Repeats.

Yan B, Suen M, Xu N, Lu C, Liu C, Zhu G Int J Mol Sci. 2025; 26(4).

PMID: 40004056 PMC: 11855686. DOI: 10.3390/ijms26041591.

Small molecules reveal differential shifts in stability and protein binding for G-quadruplex RNA.

Martyr J, Zafferani M, Bailey M, Zorawski M, Montalvan N, Muralidharan D bioRxiv. 2025; .

PMID: 39990451 PMC: 11844376. DOI: 10.1101/2025.02.10.637408.

Evaluating the Performance of Peak Calling Algorithms Available for Intracellular G-Quadruplex Sequencing.

Wang Y, Xiao K, Tao T, Zhang R, Shu H, Sun X Int J Mol Sci. 2025; 26(3).

PMID: 39941033 PMC: 11818603. DOI: 10.3390/ijms26031268.

SERBP1 interacts with PARP1 and is present in PARylation-dependent protein complexes regulating splicing, cell division, and ribosome biogenesis.

Breunig K, Lei X, Montalbano M, Guardia G, Ostadrahimi S, Alers V Elife. 2025; 13.

PMID: 39937575 PMC: 11820137. DOI: 10.7554/eLife.98152.

References

Bhattacharjee S, Chakraborty S, Chorell E, Sengupta P, Bhowmik S . Importance of the hydroxyl substituents in the B-ring of plant flavonols on their preferential binding interactions with VEGF G-quadruplex DNA: Multi-spectroscopic and molecular modeling studies. Int J Biol Macromol. 2018; 118(Pt A):629-639. DOI: 10.1016/j.ijbiomac.2018.06.115. View

Phatak P, Cookson J, Dai F, Smith V, Gartenhaus R, Stevens M . Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer. 2007; 96(8):1223-33. PMC: 2360152. DOI: 10.1038/sj.bjc.6603691. View

Castle J, Uduman M, Pabla S, Stein R, Buell J . Mutation-Derived Neoantigens for Cancer Immunotherapy. Front Immunol. 2019; 10:1856. PMC: 6693295. DOI: 10.3389/fimmu.2019.01856. View

Kim M, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley L . Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc. 2002; 124(10):2098-9. DOI: 10.1021/ja017308q. View

Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K . Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia. 2003; 17(3):560-7. DOI: 10.1038/sj.leu.2402825. View

Chu B, Zhang Y, Liu H, Bai Y, Zuo X, Lu M . [Induction of apoptosis of leukemic tumor cells in mouse model with G-quadruplex ligand Tel03]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18(1):57-60. View

Brown R, Danford F, Gokhale V, Hurley L, Brooks T . Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem. 2011; 286(47):41018-27. PMC: 3220475. DOI: 10.1074/jbc.M111.274720. View

Pagano A, Iaccarino N, Abdelhamid M, Brancaccio D, Garzarella E, Di Porzio A . Common G-Quadruplex Binding Agents Found to Interact With i-Motif-Forming DNA: Unexpected Multi-Target-Directed Compounds. Front Chem. 2018; 6:281. PMC: 6066642. DOI: 10.3389/fchem.2018.00281. View

Faudale M, Cogoi S, Xodo L . Photoactivated cationic alkyl-substituted porphyrin binding to g4-RNA in the 5'-UTR of KRAS oncogene represses translation. Chem Commun (Camb). 2011; 48(6):874-6. DOI: 10.1039/c1cc15850c. View

10.

Su L, Zheng H, Li Z, Qiu J, Chen S, Liu J . Mechanistic studies on the anticancer activity of 2,4-disubstituted quinazoline derivative. Biochim Biophys Acta. 2014; 1840(10):3123-30. DOI: 10.1016/j.bbagen.2014.07.004. View

11.

He J, Liu H, Li Z, Tan J, Ou T, Huang S . New quinazoline derivatives for telomeric G-quadruplex DNA: effects of an added phenyl group on quadruplex binding ability. Eur J Med Chem. 2013; 63:1-13. DOI: 10.1016/j.ejmech.2013.01.051. View

12.

Micheli E, Altieri A, Cianni L, Cingolani C, Iachettini S, Bianco A . Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. Biochimie. 2016; 125:223-31. DOI: 10.1016/j.biochi.2016.04.008. View

13.

Weinstein I . Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis. 2000; 21(5):857-64. DOI: 10.1093/carcin/21.5.857. View

14.

Boddupally P, Hahn S, Beman C, De B, Brooks T, Gokhale V . Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. J Med Chem. 2012; 55(13):6076-86. PMC: 3395776. DOI: 10.1021/jm300282c. View

15.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

16.

Biffi G, Tannahill D, Miller J, Howat W, Balasubramanian S . Elevated levels of G-quadruplex formation in human stomach and liver cancer tissues. PLoS One. 2014; 9(7):e102711. PMC: 4102534. DOI: 10.1371/journal.pone.0102711. View

17.

Xiong Y, Su H, Lv P, Ma Y, Wang S, Miao H . A newly identified berberine derivative induces cancer cell senescence by stabilizing endogenous G-quadruplexes and sparking a DNA damage response at the telomere region. Oncotarget. 2015; 6(34):35625-35. PMC: 4742130. DOI: 10.18632/oncotarget.5521. View

18.

Local A, Zhang H, Benbatoul K, Folger P, Sheng X, Tsai C . APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells. Mol Cancer Ther. 2018; 17(6):1177-1186. DOI: 10.1158/1535-7163.MCT-17-1209. View

19.

Marchetti C, Zyner K, Ohnmacht S, Robson M, Haider S, Morton J . Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. J Med Chem. 2018; 61(6):2500-2517. PMC: 5867665. DOI: 10.1021/acs.jmedchem.7b01781. View

20.

Todd A, Johnston M, Neidle S . Highly prevalent putative quadruplex sequence motifs in human DNA. Nucleic Acids Res. 2005; 33(9):2901-7. PMC: 1140077. DOI: 10.1093/nar/gki553. View